For the next-generation cell and gene therapies, we must rethink design and controls, and we must reframe the problem from modality to architecture.
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
- The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Overcoming Analytical Bottlenecks In Oligonucleotide Drug Development With Automation
Growing oligonucleotide complexity is straining traditional analytical workflows. See how automated LC‑UV‑MS processing offers a scalable way to boost throughput and reduce manual effort.
-
An Innovative Approach To Streamline Raman Implementation
Standard methods for building Raman spectroscopy models are often time-consuming and resource-intensive. Explore one-batch calibration and how its performance compares to other modeling techniques.
-
Rapid Automated Selection Of Mammalian Cell Colonies
Discover how a new technology cultivates mammalian cells into clonal colonies and images them using fluorescent assays to isolate clonal cell populations based on surface protein expression.
-
Testing The Transduction Of AAV-Based Therapeutics
Organ-on-a-Chip technology has emerged as a solution to the limitations of conventional preclinical models. Learn how Liver-Chips can be used to test the delivery efficiency and safety of AAV vectors.
-
Monitoring Bioprocesses In A Light Environment Using Raman Spectroscopy
Discover an advanced solution to facilitate the implementation of Raman technology at both laboratory and manufacturing scales in a normal light environment.
-
Cell Culture Automation Of The 3D Cancer Spheroid Assay
Discover how automated 3D cell culture methods enhance efficiency and consistency in high-throughput drug screening to accelerate the discovery of new anti-cancer therapies.
-
Jaw Crimping vs. Rotary Crimping: Enhancing Aseptic Assurance
Beyond a simple mechanical step, crimping is a critical control point. We examine how advanced rotary technology provides superior seal quality, particulate control, and data-driven compliance assurance.
-
Enabling CDMOs To Focus On Core Priorities
Explore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.
-
Physiologix™ Serum Replacement Performance On Mesenchymal Stem Cells
Learn about the effectiveness of a xeno-free serum replacement in mesenchymal stem cell (MSC) culture and its potential to enhance cell growth and reduce variability compared to fetal bovine serum.
-
Annex 1: Sterile Fill/Finish For Early Phase Clinical Supplies
Meeting stringent requirements for sterile fill/finish operations hinges on robust contamination control strategies, advanced isolator technology, and rigorous integrity testing to ensure patient safety.
NEWSLETTER ARCHIVE
- 02.09.26 -- Strategies For Multi-Modal Success And Annex 1 Compliance
- 02.09.26 -- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
- 02.06.26 -- New Podcast Episodes: Putting Pressure On CDMOs, BoB@JPM, Building Safer CRISPR Medicines For CVD
- 02.06.26 -- Sales & Operations Planning For Small Teams: Aligning Clinical Supply
- 02.05.26 -- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections